Verascity Science

We’re excited to announce the formation of Petauri Advance—a forward-thinking medical communications platform! This launch unites our acclaimed agencies—Blendworks, Bluprint Oncology, Cogency, FORCE Communications-Powered by Petauri™ (including DRIVE, PROPEL, and MOMENTUM), and Verascity Science—under one group, integrating and optimizing healthcare communications for the life sciences industry.   To learn more about how Petauri Advance can help your organization clarify complex science and deliver impactful medical communications, please visit https://lnkd.in/e6G96UY4 #MedicalCommunications #HealthcareInnovation #ScientificStrategy #Pharma #Biotech

The healthcare industry is at a pivotal moment, generating approximately 30% of the world’s data––and this trend continues to grow at an astonishing rate. One reason: 94% of healthcare professionals agree that data-driven approaches create new opportunities for clinicians and patients, improving outcomes, optimizing operations, enhancing decision making, and more. Our expertise in data analytics empowers our clients to make strategic decisions that speed access to medical breakthroughs by identifying trends, optimizing workflows, and delivering personalized solutions. To advance your team's data & analytics capabilities, contact us at https://lnkd.in/eadTaaSM #HealthTech #DataAndAnalytics #Healthcare #HealthcareInnovation #HealthcareSolutions #HealthData https://lnkd.in/eUTj-crn

There is a significant R&D portfolio reallocation underway as big pharma expands their investment in #advancedtherapies Developing and commercializing these innovative therapies will require new go-to-market approaches to stakeholder communications to fully realize potential.

Happy Father's Day from Verascity Science 😊

Check out the carousel below, which highlights a small sample of activities planned in Atlanta over the next week to honor and commemorate hashtag #Juneteenth. How will you celebrate Juneteenth? #FreedomDay #Juneteenth2024 #Georgia

I recently attended #asco24 in Chicago in early June. The excitement for advanced therapies in tumor types with high unmet clinical needs was palpable. Novel treatment modalities like ADCs, radioligand therapies, T cell engagers, and cell therapies are leading to significant improvements in outcomes and survival rates. Navigating through the vast amount of new clinical data at ASCO can be challenging, particularly with the dominance of studies evaluating immunotherapies and checkpoint inhibitors in the news cycle. ⭕ For a deeper dive into the advanced therapy studies that transcend the media headlines, check out my special post-ASCO podcast episode. This recap aims to shed light on key insights beyond what's making the news. If you crave more information or specifics about any of the new data shared at the ASCO conference, feel free to DM me on LinkedIn. Find the link to the podcast episode below ⬇ #advancedtherapies #raredisease #oncology #hematology #podcast

#ICYMI: Popular Episodes of "Rx for Biotech" Featuring Emerging Radiopharmaceutical Companies! The radiopharmaceutical market is booming, and we wanted to share two incredible episodes you don’t want to miss, highlighting some of the most innovative companies in the field.

We’re attending ASCO 2024!   Meet with the Verascity Science team in Chicago from May 31 through June 4!   We’re eager to learn about your latest projects and discuss how we can support the development and commercialization of your #advancedtherapies.   Meet us at #ASCO24 by messaging Christopher Leidli to schedule a time to meet...we look forward to seeing you and discussing all the latest clinical developments in #oncology Bluprint Oncology Brightly Network

Important overview of the top #melanoma clinical data that will be presented at #ASCO24 beginning next weekend! ➡ Omid Hamid outlines his "must see" ASCO 2024 presentations that will be presented. 🔹 Christian U. Blank - Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial. 🔹 Jeffrey S. Weber - Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial. 🔹 Sajeve Thomas - Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A. 🔹 Omid Hamid - Phase 1 safety and efficacy of IMC-F106C, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM). 🔹 Paolo A. Ascierto - Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO + RELA + IPI) in advanced melanoma: Results from RELATIVITY-048. https://lnkd.in/gjMGRgiY #skincancer #oncology #advancedtherapies #celltherapy #clinicaldevelopment

Great discussion during todays Scientific Symposium on #ai and its impact on #cellandgenetherapies during the American Society of Gene 🧬 and Cell Therapy (ASGCT) annual meeting! Many thanks to my Symposium Co-Chair Catherine Blanchard Gillespie and to the speakers David Cheng Rory Bricker-Anthony, PhD Priyanka Shah